US2008233142A1PendingUtilityA1
Use of penetration enhancers and barrier disruption methods to enhance the immune response of an antigen
Est. expiryNov 14, 2016(expired)· nominal 20-yr term from priority
A61K 39/00A61K 9/0014A61K 31/739A61K 39/107Y02A50/30A61K 39/12C12N 2760/16034A61K 2039/54A61K 39/05C12N 2740/16234A61K 2039/55505A61K 39/39A61K 2039/55522A61K 39/102A61K 9/06A61K 2039/55533A61K 9/127A61K 39/205A61K 2039/70C12N 2760/20134A61K 2039/55561A61K 2039/55566A61K 2039/55544A61K 47/12A61K 9/107A61K 39/0258A61K 47/08A61K 2039/55572A61K 9/08A61K 39/145A61K 35/74A61K 9/7023A61K 2039/55511A61K 2039/53A61K 47/10A61K 39/008
69
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A transcutaneous immunization system where the topical application of an adjuvant and an antigen or nucleic acid encoding for an antigen, to intact skin induces a systemic or mucosol antibody response. The immune response so elicited can be enhanced by physical or chemical skin penetration enhancement.
Claims
exact text as granted — not AI-modified1 - 59 . (canceled)
60 : A method for inducing an antigen-specific immune response in a subject comprising:
a) pretreating an area of the skin of the subject, wherein pretreating comprises applying means for enhancing penetration and/or barrier disruption of the skin; and b) applying a formulation transcutaneously to the pretreated area to induce an antigen-specific immune response, wherein the formulation comprises:
1) an antigen in an amount effective to induce an antigen-specific immune response;
2) a pharmaceutically acceptable carrier;
wherein pretreating enhances the immune response.
61 : The method of claim 60 , wherein pretreating comprises applying to the skin a chemical means, a physical means, a mechanical means, a hydration means, or a combination thereof.
62 : The method of claim 60 , wherein pretreating comprises applying a chemical to the skin.
63 : The method of claim 62 , wherein the chemical is an alcohol, an acetone, a detergent, a depilatory agent, a keratinolytic formulation, a cream, or a combination thereof.
64 : The method of claim 60 , wherein pretreating comprises applying a device.
65 : The method of claim 64 , wherein the device is selected from the group consisting of a propellant device, a device comprising tines, a device comprising microneedles, a device comprising a tine disk, a tape stripping device, a gas powered gun, a swab, an emery board, an abrasive pad, an electroporation device, an ultrasound device, and an iontophoresis device.
66 . (canceled)
67 : The method of claim 60 , wherein the antigen is a nucleic acid encoding an antigen, carbohydrate, a glycolipid, a glycoprotein, a lipid, a lipoprotein, a phospholipid, a polypeptide, a protein, a fusion protein, or chemical conjugate of a combination thereof.
68 : The method of claim 60 , wherein the antigen is derived from a pathogen.
69 : The method of claim 68 , wherein the pathogen is a virus, a bacterium, a parasite, or a fungus.
70 : The method of claim 69 , wherein the virus is an influenza virus or a rabies virus.
71 : The method of claim 70 , wherein the antigen is hemagglutinin A.
72 : The method of claim 69 , wherein the bacterium is E. coli or Bacillus anthracis.
73 : The method of claim 72 , wherein the antigen is E. coli heat-labile enterotoxin (LT).
74 : The method of claim 72 , wherein the antigen is a nucleic acid encoding E. coli heat-labile enterotoxin (LT).
75 : The method of claim 60 , wherein the antigen is a pathogen.
76 : The method of claim 75 , wherein the pathogen is a virus, a bacterium, a parasite, or a fungus.
77 : The method of claim 76 , wherein the virus is a whole virus, a live virus, an attenuated live virus, an inactivated virus, a detergent treated virus, or a combination thereof.
78 : The method of claim 77 , wherein the virus is an influenza virus or a rabies virus.
79 : The method of claim 78 , wherein the influenza virus comprises hemagglutinin A.
80 : The method of claim 76 , wherein the bacterium is E coli or Bacillus anthracis.
81 : The method of claim 80 , wherein the E. coli comprises E. coli heat-labile enterotoxin (LT).
82 : The method of claim 60 , wherein the antigen is a multivalent antigen.
83 : The method of claim 60 , wherein the antigen activates an antigen presenting cell.
84 : The method of claim 83 , wherein the antigen presenting cell is a Langerhans cell or a dermal dendritic cell.
85 : The method of claim 60 , wherein the antigen is a whole microorganism, a whole cell, or a virion.
86 : The method of claim 60 , wherein the formulation is applied using a patch.
87 : A method for inducing an antigen-specific immune response in a subject comprising concurrently,
a) treating an area of the skin of the subject, wherein treating comprises applying means for enhancing penetration and/or barrier disruption of the skin; and b) applying a formulation transcutaneously to the treated area to induce an antigen-specific immune response, wherein the formulation comprises:
1) an antigen in an amount effective to induce an antigen-specific immune response;
2) a pharmaceutically acceptable carrier;
wherein treating enhances the immune response.
88 : The method of claim 87 , wherein treating comprises applying to the skin a chemical means, a physical means, a mechanical means, a hydration means, or a combination thereof.
89 : The method of claim 87 , wherein treating comprises applying a chemical to the skin.
90 : The method of claim 89 , wherein the chemical is an alcohol, an acetone, a detergent, a depilatory agent, a keratinolytic formulation, a cream, or a combination thereof.
91 : The method of claim 87 , wherein treating comprises applying a device.
92 : The method of claim 91 , wherein the device is selected from the group consisting of a propellant device, a device comprising tines, a device comprising microneedles, a device comprising a tine disk, a tape stripping device, a gas powered gun, a swab, an emery board, an abrasive pad, an electroporation device, an ultrasound device, and an iontophoresis device.
93 . (canceled)
94 : The method of claim 87 , wherein the antigen is a nucleic acid encoding an antigen, carbohydrate, a glycolipid, a glycoprotein, a lipid, a lipoprotein, a phospholipid, a polypeptide, a protein, a fusion protein, or chemical conjugate of a combination thereof.
95 : The method of claim 87 , wherein the antigen is derived from a pathogen.
96 : The method of claim 95 , wherein the pathogen is a virus, a bacterium, a parasite, or a fungus.
97 : The method of claim 96 , wherein the virus is an influenza virus or a rabies virus.
98 : The method of claim 97 , wherein the antigen is hemagglutinin A.
99 : The method of claim 96 , wherein the bacterium is E. coli or Bacillus anthracis.
100 : The method of claim 99 , wherein the antigen is E. coli heat-labile enterotoxin (LT).
101 : The method of claim 99 , wherein the antigen is a nucleic acid encoding E. coli heat-labile enterotoxin (LT).
102 : The method of claim 97 , wherein the antigen is a pathogen.
103 : The method of claim 102 , wherein the pathogen is a virus, a bacterium, a parasite, or a fungus.
104 : The method of claim 103 , wherein the virus is a whole virus, a live virus, an attenuated live virus, an inactivated virus, a detergent treated virus, or a combination thereof.
105 : The method of claim 104 , wherein the virus is an influenza virus or a rabies virus.
106 : The method of claim 105 , wherein the influenza virus comprises hemagglutinin A.
107 : The method of claim 103 , wherein the bacterium is E coli or Bacillus anthracis.
108 : The method of claim 107 , wherein the E. coli comprises E. coli heat-labile enterotoxin (LT).
109 : The method of claim 87 , wherein the antigen is a multivalent antigen.
110 : The method of claim 87 , wherein the antigen activates an antigen presenting cell.
111 : The method of claim 110 , wherein the antigen presenting cell is a Langerhans cell or a dermal dendritic cell.
112 : The method of claim 87 , wherein the antigen is a whole microorganism, a whole cell, or a virion.
113 : The method of claim 87 , wherein the formulation is applied using a patch.
114 : The method of claim 67 , wherein the nucleic acid is a DNA encoding an influenza protein.
115 : The method of claim 94 , wherein the nucleic acid is a DNA encoding an influenza protein.
116 : The method of claim 73 , wherein the LT is a genetically altered toxin.
117 : The method of claim 74 , wherein the LT is a genetically altered toxin.
118 : The method of claim 81 , wherein the LT is a genetically altered toxin.
119 : The method of claim 100 , wherein the LT is a genetically altered toxin.
120 : The method of claim 101 , wherein the LT is a genetically altered toxin.
121 : The method of claim 108 , wherein the LT is a genetically altered toxin.Join the waitlist — get patent alerts
Track US2008233142A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.